Ivabradine Ab

Ivabradine, the active ingredient in Ivabradine Ab, is a If channel inhibitor presented as an oral tablet for oral use. It treats chronic stable angina pectoris and heart failure with reduced ejection fraction in appropriate patients, helping to lower heart rate without affecting contractility.

GNH USA supplies Ivabradine Ab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine is used in cardiovascular conditions where heart‑rate reduction improves outcomes.

Chronic stable angina pectoris: reduces the frequency of angina attacks by lowering heart rate. Heart failure with reduced ejection fraction (NYHA class II–III): improves exercise capacity and lowers risk of hospitalization. Stable coronary artery disease: helps control heart rate to relieve ischemic symptoms.

Ivabradine may cause a range of adverse reactions, most of which are related to its heart‑rate‑lowering action or visual perception.

Common Side Effects: - Bradycardia: heart rate falls below the intended range. - Phosphenes (visual luminous phenomena): transient bright spots in vision. - Headache: mild to moderate discomfort. - Dizziness or light‑headedness. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical attention. - Atrial fibrillation or other arrhythmias. - Severe hypotension with syncope. - Symptomatic heart block. - Persistent visual impairment. - Allergic reactions such as rash or angioedema.

Before prescribing ivabradine, clinicians should consider several safety measures.

Cardiovascular assessment: confirm resting heart rate and sinus rhythm. Concomitant beta‑blocker use: monitor for excessive bradycardia when combined. CYP3A4 inhibitors: avoid strong inhibitors or adjust therapy. Pregnancy and lactation: use only if potential benefit justifies potential risk. Renal or hepatic impairment: evaluate need for dose modification. Store at room temperature: keep in original container, protect from moisture and light.

Ivabradine interacts with several medicines that affect heart rate or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause toxic levels. - Other heart‑rate‑lowering agents (beta‑blockers, diltiazem, verapamil): risk of severe bradycardia. - Pacemaker dependence: may interfere with device function.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): monitor heart rate. - Digoxin: observe for additive effects on cardiac conduction. - Antihypertensives: watch for excessive blood‑pressure reduction. - Diuretics: assess electrolyte balance and volume status.